Results 51 to 60 of about 36,199 (325)
Quality of Clinical Information in Pregnancy Pharmacovigilance Data Sources-A Contribution of the ConcePTION Project. [PDF]
Pharmacoepidemiol Drug SafABSTRACT Purpose Good documentation of adverse events related to medicines is essential for the assessment of safety signals. Information on the clinical quality of primary pregnancy safety data sources is lacking. The objective of this study was to assess the differences in clinical quality of various sources of primary pregnancy pharmacovigilance (PV)
van Rijt-Weetink YRJ +7 more
europepmc +2 more sources
Pharmacoepidemiology and Drug Safety, 2021 Consensus is needed on conceptual foundations, terminology and relationships among the various self‐controlled “trigger” study designs that control for time‐invariant confounding factors and target the association between transient exposures (potential ...
S. Cadarette +9 more
semanticscholar +1 more source
Interactive exploration of population scale pharmacoepidemiology datasets
, 2020 Population-scale drug prescription data linked with adverse drug reaction (ADR) data supports the fitting of models large enough to detect drug use and ADR patterns that are not detectable using traditional methods on smaller datasets. However, detecting
Abadi M. +4 more
core +1 more source
JID Innovations, 2023 The U.S. Food and Drug Administration and clinical guidelines use evidence from pharmacoepidemiology studies to inform prescribing decisions and fill evidence gaps left by randomized controlled trials (RCTs).
Sebastian Schneeweiss +1 more
doaj
Time‐related biases in perinatal pharmacoepidemiology: A systematic review of observational studies
Pharmacoepidemiology and Drug Safety, 2022 Time‐related biases, such as immortal time and time‐window bias, frequently occur in pharmacoepidemiologic research. However, the prevalence of these biases in perinatal pharmacoepidemiology is not well understood.
U. Ukah +5 more
semanticscholar +1 more source
Trends and uptake of new formulations of controlled-release oxycodone in Canada [PDF]
, 2018 Purpose: This study investigated the impact of changing availability of tamper‐deterrent and non‐tamper‐deterrent oxycodone on prescribing patterns of controlled‐release oxycodone across Canada.
Caetano, Patricia +6 more
core +2 more sources
Response to "Aromatase Inhibitors and Dementia Risk: Putting Safety Into Perspective". [PDF]
Pharmacol Res PerspectPharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
Yuste MT +3 more
europepmc +2 more sources
Pharmacoepidemiology in pregnancy
Therapies, 2019 Taking a medication is usually a challenge for a pregnant woman as the beneficial drug effect on the mother has to be considered regarding its potential adverse effects, not only for her but also for her unborn child. As medication use is common in pregnant women, by chance or necessity, it gives the opportunity to evaluate the consequences of prenatal
Agnès Sommet +6 more
openaire +4 more sources
Immunosuppressants and risk of Parkinson disease [PDF]
, 2018 We performed a population-based case-control study of United States Medicare beneficiaries age 60-90 in 2009 with prescription data (48,295 incident Parkinson disease cases and 52,324 controls) to examine the risk of Parkinson disease in relation to use ...
Camacho-Soto, Alejandra +5 more
core +2 more sources
Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. [PDF]
, 2015 BACKGROUND: The case-crossover (CXO) and self-controlled case series (SCCS) designs are increasingly used in pharmacoepidemiology. In both, relative risk estimates are obtained within persons, implicitly controlling for time-fixed confounding variables ...
Alvarez, Arturo +16 more
core +8 more sources